Posts tagged side effects
#465: Personalizing GLP-1 Medications: The Role of Genetics in Weight Loss and Side Effects With Noura Abul-Husn M.D. Ph.D
#465: Personalizing GLP-1 Medications: The Role of Genetics in Weight Loss and Side Effects With Noura Abul-Husn M.D. Ph.D

Today, I’m joined by the incredible Dr. Nora Abdul-Hussein, a physician-scientist, medical geneticist, and one of the leading voices in the field of genomic medicine. In this episode, Dr. Abdul-Hussein and I dig into a huge question—why do two people taking the exact same GLP-1 medication have such wildly different results, from weight loss to side effect profiles? She shares her unique path from internal medicine to cutting-edge population genomics, and how her work at 23andMe is beginning to answer some of medicine’s toughest puzzles.

Read More
GLP-1s & Peptides, Weight Loss, Genetics & GenomicsLorenz Ralph GañoGLP-1 medications, weight loss, pharmacogenomics, genetic variants, personalized medicine, genetic predisposition, type 2 diabetes, nausea and vomiting, side effects, GLP-1 receptor gene, GIP receptor gene, semaglutide, tirzepatide, genome-wide association study, pharmacogenetics, polygenic risk score, genetic ancestry, healthspan, longevity, metabolic health, prevention, biomarkers, ancestry testing, 23andMe, personalized interventions, clinical trials, obesity stigma, actionable genes, newborn sequencing, data privacy
#449: I Never Said That! - Dr. Tyna Moore on How Her GLP-1 Microdosing Message Was Misunderstood and What She Actually Recommends
#449: I Never Said That! - Dr. Tyna Moore on How Her GLP-1 Microdosing Message Was Misunderstood and What She Actually Recommends

Today, I’m sitting down with the trailblazing Dr. Tyna Moore, a pioneer in reframing the conversation around GLP-1 medications. Instead of focusing solely on weight loss, Dr. Moore reveals how these powerful molecules can open a critical window to reset our health story—if we’re willing to harness that opportunity wisely.

Read More
Weight Loss, Nutrition & FitnessLorenz Ralph GañoGLP1, microdosing, weight loss, metabolic health, inflammation, autoimmune conditions, muscle mass, peptides, bioregulators, strength training, insulin resistance, Tirzepatide, Semaglutide, Retatrutide, metabolic signaling, liver fat, SIBO, digestive enzymes, lifestyle intervention, chronic pain, PCOS, metabolic syndrome, mitochondrial health, senescent cells, immunosenescence, gut health, personalized dosing, side effects, protein digestion, HRT (hormone replacement therapy), neuroplasticity